Jaron Brown Womens Jersey Drugs Generic: The Medicines Company (NASDAQ:MDCO), Mylan Inc (NASDAQ:MYL), Horizon Pharma Inc (NASDAQ:HZNP), Zoetis Inc (NYSE:ZTS) | Gaining Green

Drugs Generic: The Medicines Company (NASDAQ:MDCO), Mylan Inc (NASDAQ:MYL), Horizon Pharma Inc (NASDAQ:HZNP), Zoetis Inc (NYSE:ZTS)

Posted by on Jul 09, 2014

The Medicines Company (NASDAQ:MDCO) announced that the European Medicines Agency (EMA) the Committee for Medicinal Products for Human Use (CHMP) and the European Commission have granted market authorization renewal for Angiox® (bivalirudin) following a review of the latest clinical safety and efficacy data as well as the Angiox risk management plan. The CHMP recommendation for the renewal of the marketing authorization for Angiox reconfirms its favorable risk-benefit profile.The Medicines Company (NASDAQ:MDCO) net profit margin is 3.10% and weekly performance is -5.95%. On last trading day company shares ended up $27.33. Analysts mean target price for the company is $33.10. The Medicines Company (NASDAQ:MDCO) distance from 50-day simple moving average is -0.55%.

Mylan Inc. (Nasdaq: MYL) announced that it will host a conference call and live webcast on Thursday, Aug. 7, 2014, at 10:00 a.m. ET to review the company’s financial results for the second quarter and first half ended June 30, 2014. Mylan will release its financial results on Aug. 7 before the market opens. Mylan Inc (NASDAQ:MYL) shares fell -0.57% in last trading session and ended the day on $50.27. MYL Gross Margin is 44.80% and its return on assets is 4.50%. Mylan Inc (NASDAQ:MYL) quarterly performance is 3.86%.

Investment analysts at Piper Jaffray began coverage on shares ofHorizon Pharma (NASDAQ:HZNP) in a note issued to investors on Monday. The firm set an “overweight” rating on the stock. Horizon Pharma Inc (NASDAQ:HZNP) shares moved down -4.58% in last trading session and was closed at $15.01, while trading in range of $14.62-$15.65. Horizon Pharma Inc (NASDAQ:HZNP) year to date performance is 96.98%.

Shares of Zoetis (NYSE:ZTS) have received an average rating of “Buy” from the nine brokerages that are covering the company. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have issued a buy recommendation on the company. Zoetis Inc (NYSE:ZTS) ended the last trading day at $32.48. Company weekly volatility is calculated as 0.93% and price to cash ratio as 32.16. Zoetis Inc (NYSE:ZTS) showed a positive weekly performance of 0.65%.

Leave a Reply

Your email address will not be published. Required fields are marked *

 Brendan Langley Womens Jersey